Menu
Back to Journals » Stem Cells and Cloning: Advances and Applications » Volume 6
Endogenous cardiac stem cells for the treatment of heart failure
Authors Fuentes, Kearns-Jonker M
Received 17 November 2012
Accepted for publication 17 January 2013
Published 25 March 2013 Volume 2013:6 Pages 1—12
DOI https://doi.org/10.2147/SCCAA.S29221
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Tania Fuentes, Mary Kearns-Jonker
Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA, USA
Abstract: Stem cell-based therapies hold promise for regenerating the myocardium after injury. Recent data obtained from phase I clinical trials using endogenous cardiovascular progenitors isolated directly from the heart suggest that cell-based treatment for heart patients using stem cells that reside in the heart provides significant functional benefit and an improvement in patient outcome. Methods to achieve improved engraftment and regeneration may extend this therapeutic benefit. Endogenous cardiovascular progenitors have been tested extensively in small animals to identify cells that improve cardiac function after myocardial infarction. However, the relative lack of large animal models impedes translation into clinical practice. This review will exclusively focus on the latest research pertaining to humans and large animals, including both endogenous and induced sources of cardiovascular progenitors.
Keywords: Isl1, iPSC, large animal, c-kit, cardiosphere
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.